International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Commentary: Cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion

computer with words expert commentary
Johann Gudjonsson Headshot

Johann Gudjonsson, MD, PhD
University of Michigan
Ann Arbor, Michigan, United States
IPC Board Member

PUBLICATIONS

Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have a low prevalence of SARS-CoV-2 seroconversion. Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss MM, Heppt F, Meder C, Atreya R, Klenske E, Dietrich P, Abdullah A, Kliem T, Corte G, Morf H, Leppkes M, Kremer AE, Ramming A, Pachowsky M, Schuch F, Ronneberger M, Kleinert S, Maier C, Hueber AJ, Manger K, Manger B, Berking C, Tenbusch M, Überla K, Sticherling M, Neurath MF, Schett G. Nat Commun. 2020 Jul 24;11(1):3774. doi: 10.1038/s41467-020-17703-6. PMID: 32709909; PMCID: PMC7382482.

COMMENTARY

Do Biologics Protect Against COVID-19 Infection?

In a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments.  This patient cohort was compared against subjects with IMIDs, not on cytokine inhibitors, health care workers, and healthy controls.   The findings from this study showed that patients with IMID on cytokine inhibitors had a lower prevalence of anti-SARS-CoV-2 IgG response compared to the other three cohorts.  To assess whether this could be accounted for by differences in social exposure between the groups, the investigators assessed exposure risk variables in the four groups and found those to be similar between the two IMID groups and less than that of health care workers.  These findings led the authors to conclude that patients with IMIDs on cytokine inhibitor therapies have reduced susceptibility to SARS-CoV2 infection compared with patients not receiving cytokine-inhibitors, as well as the general population.

While these findings are highly intriguing, they have to be taken with caution.  Thus, while the findings described here are significant, they are based on very small sample sizes and lack validation from an independent cohort.  Furthermore, using a survey to control for exposure is likely inadequate as it may not capture subtle changes in behavior that are not easily caught on survey questionnaires.  In addition, while these treatments inhibit specific inflammatory pathways and may be protective against more severe COVID-192, it is hard to envision how they’d prevent seroconversion of exposed patients.  This is supported by studies showing blunted, but not absent, vaccination responses to influenza vaccine3.  Lastly, if the implications of this study hold true, it would also have potential implications regarding the utility of vaccinating patients for COVID while on biologics.

In summary, while these findings are intriguing, the message from this paper that patients with IMIDs on biologics are protected against COVID-19 infection has to be taken with great caution. More extensive and robust studies are required before we can confidently determine that biologics protect against SARS-CoV-2 infection.

Reference:

  1. Simon D, et al.  Nat Communications 2020, 3774
  2. Winthrop KL, et al.  Ann Rheum Disease, 2021 80(2):269-271
  3. Gelinck LBS, et al.  Ann Rheum Dis 2008, 67(5):713-6.

Categories

Tags

Recent Posts

Expert Insights IPC and IFPA CEO

IFPA and IPC Partnership One Year Later — Joining the Clinical and Patient Perspectives

New Councilor Headshots

Meet Our Newest Councilors

IPC and IFPA strongly advocate that early diagnosis is crucial and must be available for all individuals regardless of race, ethnicity, physical ability, culture, nationality, or geographic location blog graphic

IPC and IFPA Joint Statement on Diversity and Inclusion

Also Read

Commentary -Peter van de Kerkhof headshot
Peter van de Kerkhof

Commentary: Association of Apremilast with Vascular Inflammation and Cardiometabolic Function in Patients with Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial

Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.